News

Outlook Therapeutics to Participate in Retina World Congress 2022

ISELIN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop…

2 years ago

NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder

Clearance allows for more access to non-drug, noninvasive treatment for patients suffering from MDD or OCDMALVERN, Pa., May 10, 2022…

2 years ago

EDAP TMS SA to Announce First Quarter 2022 Financial Results on May 17, 2022

Company to host conference call and webcast on, Wednesday, May 18that 8:30 am EDT LYON, France, May 10, 2022 -…

2 years ago

Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference

HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell…

2 years ago

Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing…

2 years ago

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed…

2 years ago

Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian cancer 85% enrolled with full…

2 years ago

New $90 million annual addressable market for QHSLab’s latest product, the Allergy Quick Test, branded AllergiQT™.

WEST PALM BEACH, FL, May 10, 2022 (GLOBE NEWSWIRE) -- QHSLab, Inc. (OTCQB: USAQ) a company focused on providing clinicians…

2 years ago

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated

FREMONT, CA, May 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical…

2 years ago